Here, we combined in vitro clonogenic assays with targeted sequencing of both NPM1 and FLT3-ITD to gain further insights into the cell-of-origin of NPM1-mutated and FLT3-ITD-mutated AML in diagnostic BM from nine AMLs, five NPM1+/FLT3-ITD+, and four NPM1+/FLT3-ITD (Table 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.